Supplementary Materials? CNCR-124-4342-s001. 2015. Patients received research therapy to get a median of just one 1.9 months (range, 0.03\6.0 months). Fifty\two percent of individuals transitioned to commercially\obtainable daratumumab and 37% discontinued due to progressive disease. Quality 3 AEs happened in 50% of individuals, including thrombocytopenia (15%) and anemia (14%). Significant AEs happened in 35% of… Continue reading Supplementary Materials? CNCR-124-4342-s001. 2015. Patients received research therapy to get a